175 (PB055) - Abemaciclib drug combination screening with other targeted therapies in complex multicellular tumor spheroids

Abstract

Drug combinations are frequently used to improve clinical efficacy, to minimize toxicity, and to reduce the development of resistance. Here, we investigated the growth inhibitory activity of the CDK4/6 inhibitor abemaciclib in combination with other targeted agents. Twelve well-characterized patient-.derived cancer cell lines from the NCI Patient-Derived Models Repository (https://pdmr.cancer.gov/models/database.htm) and seven established cell lines from the NCI-60 human tumor cell line panel were grown as multicellular 3D complex spheroids.